Suppr超能文献

体重减轻时抑郁症状的增加:与葡萄糖稳态及甲状腺功能的关联

Increase in depression symptoms with weight loss: association with glucose homeostasis and thyroid function.

作者信息

Chaput Jean-Philippe, Arguin Hélène, Gagnon Claudia, Tremblay Angelo

机构信息

Division of Kinesiology, Department of Social and Preventive Medicine, Faculty of Medicine, Laval University, Quebec City, QC G1K 7P4.

出版信息

Appl Physiol Nutr Metab. 2008 Feb;33(1):86-92. doi: 10.1139/H07-137.

Abstract

The purpose of this study was to assess the potential impact of weight loss up to a state of plateau on symptoms of depression. Eleven obese men (mean body mass index (BMI)=33.4 kg.m(-2), mean age=38 y) participated in this repeated-measures, within-subjects, clinical intervention. They were subjected to a weight-loss program that consisted of a supervised diet and exercise clinical intervention. The phases investigated were (i) baseline; (ii) after 5+/-1 kg loss of body mass (phase 1); (iii) after 10+/-1 kg weight loss (phase 2); and (iv) at resistance to further weight loss (plateau). At each phase of the weight-reducing program, glucose homeostasis markers were determined using an oral glucose tolerance test (OGTT). Serum thyroid-stimulating hormone (TSH), total triiodothyronine (T3), and free thyroxine (fT4) concentrations were also measured and the Beck Depression Inventory (BDI) was administered. The weight loss plateau occurred after 7.4+/-1.9 months of intervention and corresponded to a loss of 11.2% of initial body weight (93.9% of which was from fat stores). This amount of weight loss induced a significant decrease in resting metabolic rate (RMR) (p<0.05) and a significant increase in desire to eat (p<0.05) and in depression symptoms (p<0.01) compared with baseline. Intriguingly, the glucose area below fasting values (GABF) at plateau was significantly higher as compared with other phases of the program (p<0.01). We found a strong negative correlation (r=-0.77, p<0.01) between the change in glucose concentrations at 180 min of the OGTT and the change in BDI scores between plateau and baseline values. Similarly, highly significant relationships were found between the change in T3 or fT4 concentrations and the change in BDI scores (r=-0.71 and r=-0.68, respectively; p<0.01). Weight loss until plateauing is associated with a trend toward hypoglycemia at the end of the oral glucose challenge and with a decrease in T3 and fT4 levels. These physiological changes are shown to be highly linked with the increase in depression symptoms observed at plateau. Taken together, these data emphasize the relevance of caution and reasonable objectives when prescribing a weight reduction program to obese individuals.

摘要

本研究的目的是评估体重减轻直至平台期对抑郁症状的潜在影响。11名肥胖男性(平均体重指数(BMI)=33.4 kg·m⁻²,平均年龄=38岁)参与了这项重复测量、受试者自身对照的临床干预研究。他们接受了一项减肥计划,该计划包括有监督的饮食和运动临床干预。研究的阶段包括:(i)基线期;(ii)体重减轻5±1 kg后(阶段1);(iii)体重减轻10±1 kg后(阶段2);以及(iv)体重不再减轻(平台期)。在减肥计划的每个阶段,使用口服葡萄糖耐量试验(OGTT)测定葡萄糖稳态指标。还测量了血清促甲状腺激素(TSH)、总三碘甲状腺原氨酸(T3)和游离甲状腺素(fT4)的浓度,并进行了贝克抑郁量表(BDI)测试。干预7.4±1.9个月后出现体重减轻平台期,此时体重减轻了初始体重的11.2%(其中93.9%来自脂肪储存)。与基线相比,这种程度的体重减轻导致静息代谢率(RMR)显著降低(p<0.05),食欲和抑郁症状显著增加(p<0.05和p<0.01)。有趣的是,平台期空腹血糖值以下的葡萄糖面积(GABF)与该计划的其他阶段相比显著更高(p<0.01)。我们发现OGTT 180分钟时葡萄糖浓度的变化与平台期和基线值之间BDI评分的变化呈强烈负相关(r=-0.77,p<0.01)。同样,T3或fT4浓度的变化与BDI评分的变化之间也存在高度显著的关系(分别为r=-0.71和r=-0.68;p<0.01)。体重减轻直至平台期与口服葡萄糖耐量试验结束时低血糖倾向以及T3和fT4水平降低有关。这些生理变化与平台期观察到的抑郁症状增加高度相关。综上所述,这些数据强调了在为肥胖个体制定减肥计划时谨慎设定合理目标的重要性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验